Typology of Users of Psychedelics and Alike Psychoactive Substances in Czechia: Results of the National Online Survey

References

• Acker, L. 2020. Oregon becomes first state to legalize psychedelic mushrooms, https://www.oregonlive.com/politics/2020/11/oregon-becomes-first-state-to-legalize-psychedelic-mushrooms.html
   Google Scholar
• Aixalá, M., G. Ona, O. Parés, and J. C. Bouso. 2020. Patterns of use, desired effects, and mental health status of a sample of natural psychoactive drug users. Drugs: Education, Prevention and Policy 27 (3):191–98. Retrieved Jan 17, 2021. from doi:10.1080/09687637.2019.1611739.
   Web of Science ®Google Scholar
• Belouin, S. J., and J. E. Henningfield. 2018. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology 142:7–19. doi:10.1016/j.neuropharm.2018.02.018.
   PubMed Web of Science ®Google Scholar
• Benschop, A., M. Bujalski, K. Dabrowska, Z. Demetrovics, D. Egger, K. Felinczi, S. Henriques, Z. Kalo, G. Kamphausen, D. J. Korf, et al. 2017. New Psychoactive Substances: Transnational project on different user groups, user characteristics, extent and patterns of use, market dynamics, and best practices in prevention. NPS-transnational Project (HOME/2014/JDRU/AG/DRUG/7077). Retrieved Nov 7, 2020, from https://www.drugsandalcohol.ie/29963/
   Google Scholar
• Benschop, A., R. Urbán, M. Kapitány-Fövény, M. Hout, K. Dąbrowska, K. Felvinczi, E. Hearne, S. Henriques, Z. Kalo, G. Kamphausen, et al. 2020. Why do people use new psychoactive substances? Development of a new measurement tool in six European countries. Journal of Psychopharmacology 34 (6):026988112090495. doi:10.1177/0269881120904951.
   Web of Science ®Google Scholar
• Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa2032994.
   PubMed Web of Science ®Google Scholar
• d’Angelo, L. C., G. Savulich, and B. J. Sahakian. 2017. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. British Journal of Pharmacology 174 (19):3257–67. Retrieved Jan 13, 2021. from doi:10.1111/bph.13813.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2021. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78 (5):481–89. doi:10.1001/jamapsychiatry.2020.3285.
   PubMed Web of Science ®Google Scholar
• Decorte, T., and M. Pardal. 2020. Insights for the design of cannabis social club regulation. Legalizing Cannabis 409–426.
   Google Scholar
• Diener, E., R. A. Emmons, R. J. Larsen, and S. Griffin. 1985. The satisfaction with life scale. Journal of Personality Assessment 49 (1):71–75. doi:10.1207/s15327752jpa4901_13.
   PubMed Web of Science ®Google Scholar
• Domínguez-Clavé, E., J. Soler, J. C. Pascual, M. Elices, A. Franquesa, M. Valle, E. Alvarez, and J. Riba. 2019. Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology 236 (2):573–80. doi:10.1007/s00213-018-5085-3.
   PubMed Web of Science ®Google Scholar
• Earleywine, M., L. F. Ueno, M. N. Mian, and B. R. Altman. 2021. Cannabis-induced oceanic boundlessness. Journal of Psychopharmacology 35 (7):841–47. doi:10.1177/0269881121997099.
   PubMed Web of Science ®Google Scholar
• EMCDDA. 2020. Statistical Bulletin 2020 — prevalence of drug use. Retrieved Nov 7, 2020, from https://www.emcdda.europa.eu/data/stats2020/gps
   Google Scholar
• Fatur, K. 2021. Peculiar plants and fantastic fungi: An ethnobotanical study of the use of hallucinogenic plants and mushrooms in Slovenia. PLoS One 16 (1):e0245022. Retrieved Jan 13, 2021. from doi:10.1371/journal.pone.0245022.
   PubMed Web of Science ®Google Scholar
• Fernández-Calderón, F., C. M. Cleland, and J. J. Palamar. 2018. Polysubstance use profiles among electronic dance music party attendees in New York City and their relation to use of new psychoactive substances. Addictive Behaviors 78:85–93. Retrieved Jan 13, 2021. from. doi:10.1016/j.addbeh.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A. 2014. Making your mark in the psychedelic renaissance. MAPS Bulletin 24 (1):10–13. Retrieved Nov 5, 2020. from. https://maps.org/news-letters/v24n1/v24n1_p10-13.pdf
   Google Scholar
• Gasser, P., D. Holstein, Y. Michel, R. Doblin, B. Yazar-Klosinski, T. Passie, and R. Brenneisen. 2014. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease 202 (7):513–20. doi:10.1097/NMD.0000000000000113.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Grof, C., and S. Grof. 2017. Spiritual emergency: The understanding and treatment of transpersonal crises. International Journal of Transpersonal Studies 36 (2):30–43. doi:10.24972/ijts.2017.36.2.30.
   Google Scholar
• Hannemann, T. -V., L. Kraus, and D. Piontek. 2017. Consumption patterns of nightlife attendees in Munich: A latent-class analysis. Substance Use & Misuse 52 (11):1511–21. doi:10.1080/10826084.2017.1290115.
   PubMed Web of Science ®Google Scholar
• Johnstad, P. G. 2020b. Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences. Nordic Studies on Alcohol and Drugs 38 (1):35–49. doi:10.1177/1455072520963787.
   Web of Science ®Google Scholar
• Kettner, H., N. L. Mason, and K. P. C. Kuypers. 2019. Motives for classical and novel psychoactive substances use in psychedelic polydrug users. Contemporary Drug Problems 46 (3):304–20. Retrieved Jan 13, 2021. from doi:10.1177/0091450919863899.
   Google Scholar
• Kočárová, R., and M. Preiss. 2020. Psychedelika v péči o duševní zdraví. Československá psychologie 64:590–607.
   Google Scholar
• Lawrence, D. W., B. Sharma, R. R. Griffiths, and R. Carhart-Harris. 2021. Trends in the top-cited articles on classic psychedelics. Journal of Psychoactive Drugs 53 (4):1–16. doi:10.1080/02791072.2021.1874573.
   PubMed Web of Science ®Google Scholar
• Mravčík, V. ed. 2019. Výroční zpráva o stavu ve věcech drog v České republice v roce 2018 [Annual Report on Drug Situation 2018 – Czech Republic]. Prague: The Office of the Government of the Czech Republic.
   Google Scholar
• Postránecká, Z., Č. Vejmola, and F. Tylš. 2019. Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal? Journal of Psychedelic Studies 3 (1):19–31. doi:10.1556/2054.2019.003.
   Google Scholar
• Rogowska, A. 2015. The pattern of direct and instrumental motivation for illicit substance use. Procedia - Social and Behavioral Sciences 205:261–70. from https://reader.elsevier.com/reader/sd/pii/S1877042815050922?token=A840D6F4FB253593A192C7C1F49C628F3AC200F7EFC4BAED45B69663763BFD77FF688DE24F45F2DFE0039678722755D8&originRegion=eu-west-1&originCreation=20210506162611
   Google Scholar
• Sessa, B., and F. M. Fischer. 2015. Underground MDMA-, LSD-and 2-CB-Assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary. Drug Science, Policy and Law 2:2050324515578080. doi:10.1177/2050324515578080.
   Google Scholar
• Siegel, A. N., S. Meshkat, K. Benitah, O. Lipsitz, H. Gill, L. Lui, K. M. Teopiz, R. S. McIntyre, and J. D. Rosenblat. 2021. Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Journal of Psychiatric Research 139:71–81. doi:10.1016/j.jpsychires.2021.05.019.
   PubMed Web of Science ®Google Scholar
• Tanner-Smith, E. E. 2006 Jul 27. Pharmacological content of tablets sold as “ecstasy”: Results from an online testing service. Drug and Alcohol Dependence 83 (3):247–54. doi:10.1016/j.drugalcdep.2005.11.016.
   PubMed Web of Science ®Google Scholar
• Watts, R., and J. B. Luoma. 2020. The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science 15:92–102. doi:10.1016/j.jcbs.2019.12.004.
   Web of Science ®Google Scholar
• Wood, D. M., V. Stribley, P. I. Dargan, S. Davies, D. W. Holt, and J. Ramsey. Sep 2011. Variability in the 3,4-methylenedioxymethamphetamine content of ‘ecstasy’ tablets in the UK. Emergency Medicine Journal 28(9):764–65. doi: 10.1136/emj.2010.092270.
   PubMed Web of Science ®Google Scholar